Does Brentuximab Interact with Ketoconazole?
CDI records a moderate classification for Brentuximab and Ketoconazole. The stored summary is: Co-administration with ketoconazole, a potent CYP3A4 inhibitor, increases exposure to MMAE, which may increase the risk of adverse reactions. Closely monitor adverse reactions. The mechanism involves cyp3a4 inhibition increases mmae exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Brentuximab Class
- CD30-directed Immunoconjugate
- Ketoconazole Class
- Azole Antifungal
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A4 inhibition increases MMAE exposure
What To Tell Your Doctor or Pharmacist
If you are taking Brentuximab and your doctor is considering prescribing Ketoconazole (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider